A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors

Background A Phase I study to determine the maximum tolerated dose (MTD) and pharmacokinetics of afatinib (BIBW 2992), a novel irreversible ErbB Family Blocker, administered orally once daily in a 3-week-on/1-week-off dosing schedule. Methods Patients with advanced solid tumors received single-agent...

Descripción completa

Detalles Bibliográficos
Autores principales: Marshall, John, Hwang, Jimmy, Eskens, Ferry A. L. M., Burger, Herman, Malik, Shakun, Uttenreuther-Fischer, Martina, Stopfer, Peter, Ould-Kaci, Mahmoud, Cohen, Roger B., Lewis, Nancy L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589659/
https://www.ncbi.nlm.nih.gov/pubmed/23161335
http://dx.doi.org/10.1007/s10637-012-9890-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589659/
https://www.ncbi.nlm.nih.gov/pubmed/23161335
http://dx.doi.org/10.1007/s10637-012-9890-y

Ejemplares similares